Illumina, Inc. (ILMN) Receives Consensus Rating of “Hold” from Analysts
Illumina, Inc. (NASDAQ:ILMN) has been assigned an average rating of “Hold” from the twenty-four research firms that are currently covering the firm, MarketBeat reports. Four analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $162.30.
Several research analysts have recently commented on the company. Morgan Stanley restated an “underweight” rating and set a $122.00 price target (up from $115.00) on shares of Illumina in a research report on Monday. BidaskClub lowered Illumina from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price target for the company in a research report on Monday, July 3rd. Finally, Deutsche Bank AG restated a “hold” rating and set a $175.00 price target (up from $165.00) on shares of Illumina in a research report on Saturday, April 29th.
Illumina (NASDAQ ILMN) traded up 2.46% during trading on Tuesday, reaching $173.15. The company had a trading volume of 1,099,378 shares. The company’s 50-day moving average is $177.31 and its 200 day moving average is $165.72. The firm has a market capitalization of $25.28 billion, a price-to-earnings ratio of 35.04 and a beta of 0.84. Illumina has a 52 week low of $119.37 and a 52 week high of $189.48.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. The company had revenue of $598 million during the quarter, compared to analysts’ expectations of $590.51 million. Illumina had a return on equity of 21.21% and a net margin of 30.75%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.71 earnings per share. Equities analysts anticipate that Illumina will post $3.63 EPS for the current year.
In other news, Director A Blaine Bowman sold 3,000 shares of Illumina stock in a transaction dated Wednesday, April 12th. The stock was sold at an average price of $172.72, for a total transaction of $518,160.00. Following the sale, the director now owns 18,704 shares in the company, valued at $3,230,554.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $172.92, for a total value of $2,593,800.00. Following the sale, the director now owns 534,176 shares in the company, valued at approximately $92,369,713.92. The disclosure for this sale can be found here. Insiders have sold a total of 109,576 shares of company stock valued at $19,602,358 over the last ninety days. 1.60% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the stock. Advocacy Wealth Management Services LLC bought a new position in shares of Illumina during the first quarter valued at about $102,000. Gemmer Asset Management LLC boosted its position in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares during the period. Advisory Services Network LLC bought a new position in shares of Illumina during the first quarter valued at about $117,000. Patten Group Inc. boosted its position in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares during the period. Finally, Bronfman E.L. Rothschild L.P. boosted its position in shares of Illumina by 3.6% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock valued at $204,000 after buying an additional 42 shares during the period. Hedge funds and other institutional investors own 93.76% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.